Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNFNK7)

Drug Name
Zunsemetinib Drug Info
Synonyms
zunsemetinib; ATI-450; (R)-Zunsemetinib; Zunsemetinib [INN]; ATI450; CDD450; Zunsemetinib [USAN]; CDD-450; AX2VWG0ZCR; 1640282-42-3; 1639791-42-6; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-[2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl]-6-methylpyridin-2-one; 3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-1-{2-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5-methylpyridin-4-yl}-6-methylpyridin-2-one; UNII-AX2VWG0ZCR; Zunsemetinib M-atropisomer; Zunsemetinib [USAN:INN]; Ati 450; ATI 450 [WHO-DD]; CHEMBL3704901; SCHEMBL16279876; GTPL11681; BDBM175242; EX-A6292; WHO 11983; AKOS040756965; HY-139553A; MS-29543; HY-139553; CS-0204147; CS-0374185; US9115089, 49; (-)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (1(2H),4'-Bipyridin)-2-one, 3-chloro-4-((3,5-difluoro-2-pyridinyl)methoxy)-2'-(2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl)-5',6-dimethyl-, (-)-; (2'S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl[1(2H),4'-bipyridin]-2-one; (P)-(3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one); (p)-3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-(1,4'-bipyridin)-2-one; [1(2H),4'-Bipyridin]-2-one, 3-chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2'-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5',6-dimethyl-, (2'S)-; 1640282-44-5; 3-Chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
Indication
Disease Entry ICD 11 Status REF
Cryopyrin-associated periodic syndrome 4A60.1 Phase 2 [1]
Hidradenitis suppurativa ED92.0 Phase 2 [2]
Psoriatic arthritis FA21 Phase 2 [3]
Rheumatoid arthritis FA20 Phase 2 [4]
Cross-matching ID
PubChem CID
86291496
TTD Drug ID
DMNFNK7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting MAPK-activated protein kinase 2 (MAPKAPK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CBP-501 DMCWVPU Mesothelioma 2C51.2 Phase 1/2 [6]
MMI-0100 DMIMVEX Airway inflammation CA05 Phase 1 [7]
PMID19364658C33 DMSE1C3 Discovery agent N.A. Investigative [8]
PMID17480064C16 DM4IABG Discovery agent N.A. Investigative [9]
PF-3644022 DM6KVIA Discovery agent N.A. Investigative [10]
CMPD1 DMKNUYF Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MAPK-activated protein kinase 2 (MAPKAPK2) TTMUG9D MAPK2_HUMAN Inhibitor [5]

References

1 ClinicalTrials.gov (NCT04524858) A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05216224) A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe HS. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05511519) A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients With Moderate-to-Severe Active Psoriatic Arthritis. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT04247815) A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis. U.S.National Institutes of Health.
5 Clinical pipeline report, company report or official report of Aclaris Therapeutics
6 National Cancer Institute Drug Dictionary (drug id 577812).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094).
8 Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
9 Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.
10 A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807.
11 Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5.